Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice.
- 0
Gene-engineered CD34(+) hematopoietic stem and progenitor cells (HSPCs) can be utilized to generate an HIV-1-resistant immune system. Nevertheless, a sure threshold of transduced HSPCs is perhaps required for transplantation into mice for creating an HIV-resistant immune system.
On this examine, we mixed CCR5 knockdown by a extremely environment friendly microRNA (miRNA) lentivector with pretransplantation number of transduced HSPCs to acquire a reasonably pure inhabitants of gene engineered CD34(+) cells. Low-level transduction of HSPCs and subsequent sorting by circulate cytometry yielded >70% transduced cells.
Mice transplanted with these cells confirmed purposeful and protracted resistance to a CCR5-tropic HIV pressure: viral load was considerably decreased over months, and human CD4(+) T cells had been preserved. In a single mouse, viral mutations, ensuing presumably in a CXCR4-tropic pressure, overcame HIV resistance. Our outcomes recommend that HSPC-based CCR5 knockdown could result in environment friendly management of HIV in vivo.
We overcame a serious limitation of earlier HIV gene remedy in humanized mice wherein solely a proportion of the cells in chimeric mice in vivo are anti-HIV engineered. Our technique underlines the promising way forward for gene engineering HIV-resistant CD34(+) cells that produce a relentless provide of HIV-resistant progeny.
Lengthy-term central and effector SHIV-specific reminiscence T cell responses elicited after a single immunization with a novel lentivector DNA vaccine.
Prevention of HIV acquisition and replication requires lengthy lasting and efficient immunity. Given the state of HIV vaccine improvement, progressive vectors and immunization methods are urgently wanted to generate secure and efficacious HIV vaccines.
Right here, we developed a novel lentivirus-based DNA vector that doesn’t combine within the host genome and undergoes a single-cycle of replication. Viral proteins are constitutively expressed below the management of Tat-independent LTR promoter from goat lentivirus. We immunized six macaques as soon as solely with CAL-SHIV-IN- DNA utilizing mixed intramuscular and intradermal injections plus electroporation.
Antigen-specific T cell responses had been monitored for 47 weeks post-immunization (PI). PBMCs had been assessed straight ex vivo or after 6 and 12 days of in vitro tradition utilizing antigenic and/or homeostatic proliferation. IFN-γ ELISPOT was used to measure speedy cytokine secretion from antigen particular effector cells and from reminiscence precursors with excessive proliferative capability (PHPC).
The reminiscence phenotype and capabilities (proliferation, cytokine expression, lytic content material) of particular T cells had been examined utilizing multiparametric FACS-based assays. All immunized macaques developed lasting peripheral CD8+ and CD4+ T cell responses primarily in opposition to Gag and Nef antigens.
Throughout the major enlargement part, speedy effector cells in addition to growing numbers of proliferating cells with restricted effector capabilities had been detected which expressed markers of effector (EM) and central (CM) reminiscence phenotypes.
These responses contracted however then reemerged later in absence of antigen enhance. Sturdy PHPC responses comprising vaccine-specific CM and EM T cells that readily expanded and purchased speedy effector capabilities had been detected at 40/47 weeks PI. Altogether, our examine demonstrated {that a} single immunization with a replication-limited DNA vaccine elicited persistent vaccine-specific CM and EM CD8+ and CD4+ T cells with speedy and readily inducible effector capabilities, within the absence of ongoing antigen expression.
Immunogenicity of focused lentivectors.
To extend the security and probably efficacy of HIV-1 derived lentivectors (LVs) as an anti-cancer vaccine, we not too long ago developed the Nanobody (Nb) show know-how to focus on LVs to antigen presenting cells (APCs). On this examine, we prolong these knowledge with unique focusing on of LVs to traditional dendritic cells (DCs), that are believed to be the principle cross-presenting APCs for the induction of a TH1-conducted antitumor immune response.
The immunogenicity of those DC-subtype focused LVs was in comparison with that of broad tropism, common APC-targeted and non-infectious LVs. Intranodal immunization with ovalbumin encoding LVs induced proliferation of antigen particular CD4+ T cells, regardless of the LVs’ focusing on capacity.
Nevertheless, the cytokine secretion profile of the restimulated CD4+ T cells demonstrated that common APC focusing on induced an analogous TH1-profile because the broad tropism LVs whereas transduction of standard DCs alone induced an analogous and fewer potent TH1 profile because the non-infectious LVs. This commentary contradicts the speculation that standard DCs are crucial APCs and means that the activation of different APCs can also be significant.
Regardless of these variations, all focused LVs had been capable of stimulate cytotoxic T lymphocytes, be it to a lesser extent than broad tropism LVs. Moreover this induction was proven to be depending on sort I interferon for the focused and non-infectious LVs, however not for broad tropism LVs. Lastly we demonstrated that the APC-targeted LVs had been as potent in remedy as broad tropism LVs and as such ship on their promise as safer and efficacious LV-based vaccines.
Design of a novel integration-deficient lentivector know-how that includes genetic and posttranslational parts to focus on human dendritic cells.
As sentinels of the immune system, dendritic cells (DCs) play a necessary function in regulating mobile immune responses. One of many foremost challenges of creating DC-targeted therapies contains the supply of antigen to DCs with the intention to promote the activation of antigen-specific effector CD8 T cells.
With the objective of making antigen-directed immunotherapeutics that may be safely administered on to sufferers, Immune Design has developed a platform of novel integration-deficient lentiviral vectors that focus on and ship antigen-encoding nucleic acids to human DCs.
This platform, termed ID-VP02, makes use of a novel genetic variant of a Sindbis virus envelope glycoprotein with posttranslational carbohydrate modifications together with Vpx, a SIVmac viral accent protein, to attain environment friendly focusing on and transduction of human DCs. As well as, ID-VP02 incorporates security options in its design that embrace two redundant mechanisms to render ID-VP02 integration-deficient.
Right here, we describe the traits that enable ID-VP02 to particularly transduce human DCs, and the advances that ID-VP02 brings to traditional third-generation lentiviral vector design in addition to exhibit upstream manufacturing yields that can allow manufacturing feasibility research to be performed.
Cell-cell transmission of VSV-G pseudotyped lentivector particles
Many replicating viruses, together with HIV-1 and HTLV-1, are effectively transmitted from the cell floor of actively contaminated cells upon contact with bystander cells. In a earlier examine, we reported the extended cell floor retention of VSV-G replication-deficient pseudotyped lentivector previous to endocytic entry. Nevertheless, the competing kinetics of cell floor versus dissociation, neutralization or direct switch to different cells have acquired comparatively little consideration.
Right here we exhibit that the relative effectivity of cell-cell floor transmission can outpace “cell-free” transduction at limiting vector enter. This coincides with the extended half-life of cell certain vector however happens, in contrast to HTLV-1, with out proof for particle aggregation.
C1orf43 ORF Vector (Human) (pORF) |
|||
| ORF001431 | ABM | 1.0 ug DNA | EUR 114 |
C1orf43 ORF Vector (Human) (pORF) |
|||
| ORF001432 | ABM | 1.0 ug DNA | EUR 114 |
C1orf43 cloning plasmid |
|||
| CSB-CL874824HU1-10ug | Cusabio | 10ug | EUR 279.6 |
|
Description: A cloning plasmid for the C1orf43 gene. |
|||
C1orf43 cloning plasmid |
|||
| CSB-CL874824HU2-10ug | Cusabio | 10ug | EUR 279.6 |
|
Description: A cloning plasmid for the C1orf43 gene. |
|||
C1ORF43 Blocking Peptide |
|||
| 33R-10211 | Fitzgerald | 100 ug | EUR 216 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of C1orf43 antibody, catalog no. 70R-3822 |
|||
pCMV-SPORT6-C1orf43 |
|||
| PVT12431 | Lifescience Market | 2 ug | EUR 469.2 |
Human C1orf43 shRNA Plasmid |
|||
| 20-abx958583 | Abbexa |
|
|
pECMV-3-FLAG-C1orf43 |
|||
| PVT13021 | Lifescience Market | 2 ug | EUR 390 |
C1orf43 Recombinant Protein (Human) |
|||
| RP004291 | ABM | 100 ug | Ask for price |
C1orf43 Recombinant Protein (Human) |
|||
| RP004294 | ABM | 100 ug | Ask for price |
C1orf43 Protein Vector (Human) (pPB-C-His) |
|||
| PV005721 | ABM | 500 ng | EUR 394.8 |
C1orf43 Protein Vector (Human) (pPB-N-His) |
|||
| PV005722 | ABM | 500 ng | EUR 394.8 |
C1orf43 Protein Vector (Human) (pPM-C-HA) |
|||
| PV005723 | ABM | 500 ng | EUR 394.8 |
C1orf43 Protein Vector (Human) (pPM-C-His) |
|||
| PV005724 | ABM | 500 ng | EUR 394.8 |
C1orf43 Protein Vector (Human) (pPB-C-His) |
|||
| PV005725 | ABM | 500 ng | EUR 394.8 |
C1orf43 Protein Vector (Human) (pPB-N-His) |
|||
| PV005726 | ABM | 500 ng | EUR 394.8 |
C1orf43 Protein Vector (Human) (pPM-C-HA) |
|||
| PV005727 | ABM | 500 ng | EUR 394.8 |
C1orf43 Protein Vector (Human) (pPM-C-His) |
|||
| PV005728 | ABM | 500 ng | EUR 394.8 |
C1orf43 Protein Vector (Human) (pPB-His-MBP) |
|||
| PV330078 | ABM | 500 ng | EUR 394.8 |
C1orf43 Protein Vector (Human) (pPB-His-GST) |
|||
| PV330079 | ABM | 500 ng | EUR 394.8 |
C1orf43 Protein Vector (Human) (pPB-His-MBP) |
|||
| PV330082 | ABM | 500 ng | EUR 394.8 |
C1orf43 Protein Vector (Human) (pPB-His-GST) |
|||
| PV330083 | ABM | 500 ng | EUR 394.8 |
C1orf43 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV707944 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf43 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV707945 | ABM | 1.0 ug DNA | EUR 448.8 |
C1orf43 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV707946 | ABM | 1.0 ug DNA | EUR 448.8 |
C1orf43 sgRNA CRISPR Lentivector set (Human) |
|||
| K0205701 | ABM | 3 x 1.0 ug | EUR 406.8 |
C1orf43 Protein Vector (Human) (pPM-N-D-C-HA) |
|||
| PV330080 | ABM | 500 ng | EUR 662.4 |
C1orf43 Protein Vector (Human) (pPM-N-D-C-His) |
|||
| PV330081 | ABM | 500 ng | EUR 662.4 |
C1orf43 Protein Vector (Human) (pPM-N-D-C-HA) |
|||
| PV330084 | ABM | 500 ng | EUR 662.4 |
C1orf43 Protein Vector (Human) (pPM-N-D-C-His) |
|||
| PV330085 | ABM | 500 ng | EUR 662.4 |
C1orf43 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K0205702 | ABM | 1.0 ug DNA | EUR 184.8 |
C1orf43 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K0205703 | ABM | 1.0 ug DNA | EUR 184.8 |
C1orf43 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0205704 | ABM | 1.0 ug DNA | EUR 184.8 |
C1orf43 3'UTR Luciferase Stable Cell Line |
|||
| TU002013 | ABM | 1.0 ml | EUR 1825.2 |
C1orf43 3'UTR GFP Stable Cell Line |
|||
| TU052013 | ABM | 1.0 ml | EUR 1825.2 |
C1orf43 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0205705 | ABM | 3 x 1.0 ug | EUR 451.2 |
C1orf43 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0205706 | ABM | 1.0 ug DNA | EUR 200.4 |
C1orf43 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0205707 | ABM | 1.0 ug DNA | EUR 200.4 |
C1orf43 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0205708 | ABM | 1.0 ug DNA | EUR 200.4 |
Cas9 Nuclease Lentiviral Vector |
|||
| K002 | ABM | 10 ug | EUR 184.8 |
Cas9 Nickase Lentiviral Vector |
|||
| K005 | ABM | 10 ug | EUR 184.8 |
dCas9-KRAB Lentiviral Vector |
|||
| K203 | ABM | 10 ug | EUR 273.6 |
pLenti-GFP Lentiviral Control Vector |
|||
| LTV-400 | Cell Biolabs | 100 µL | EUR 741.6 |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
pSMPUW-MNDnLacZ Lentiviral Control Vector |
|||
| LTV-402 | Cell Biolabs | 10 µg | EUR 741.6 |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
Cas9 Double Mutant Lentiviral Vector |
|||
| K012 | ABM | 10 ug | EUR 643.2 |
pSMPUW-Puro Lentiviral Expression Vector |
|||
| VPK-212 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-Neo Lentiviral Expression Vector |
|||
| VPK-213 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-Hygro Lentiviral Expression Vector |
|||
| VPK-214 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-GFP-Puro Lentiviral Control Vector |
|||
| LTV-401 | Cell Biolabs | 10 µg | EUR 741.6 |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
pLenti-RFP-Puro Lentiviral Control Vector |
|||
| LTV-403 | Cell Biolabs | 100 µL | EUR 741.6 |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
pSMPUW-GFP-LC3 Lentiviral Expression Vector |
|||
| LTV-801 | Cell Biolabs | 10 µg | EUR 1444.8 |
|
Description: Expression vector contains a fusion of GFP and LC3. A separate GFP control vector is also included. |
|||
ESR1 Lentiviral Vector (Human) (pLenti-II) |
|||
| LV010008 | ABM | 1.0 ug DNA | EUR 379.2 |
pSMPUW Universal Lentiviral Expression Vector (Promoterless) |
|||
| VPK-211 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest and a gene-specific promoter into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293T or 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-IRES-Puro Lentiviral Expression Vector |
|||
| VPK-215 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-IRES-Neo Lentiviral Expression Vector |
|||
| VPK-216 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-IRES-Hygro Lentiviral Expression Vector |
|||
| VPK-217 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-IRES-Blasticidin Lentiviral Expression Vector |
|||
| VPK-219 | Cell Biolabs | 10 µg | EUR 748.8 |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
PLEC Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699401 | ABM | 1.0 ug DNA | EUR 7668 |
PLEC Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699402 | ABM | 1.0 ug DNA | EUR 7668 |
SRSF5 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699403 | ABM | 1.0 ug DNA | EUR 616.8 |
SRSF5 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699407 | ABM | 1.0 ug DNA | EUR 616.8 |
SRSF5 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699408 | ABM | 1.0 ug DNA | EUR 616.8 |
GFAP Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699409 | ABM | 1.0 ug DNA | EUR 818.4 |
GFAP Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699413 | ABM | 1.0 ug DNA | EUR 818.4 |
GFAP Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699414 | ABM | 1.0 ug DNA | EUR 818.4 |
CNIH3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699415 | ABM | 1.0 ug DNA | EUR 616.8 |
CNIH3 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699419 | ABM | 1.0 ug DNA | EUR 616.8 |
CNIH3 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699420 | ABM | 1.0 ug DNA | EUR 616.8 |
ACYP2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699421 | ABM | 1.0 ug DNA | EUR 616.8 |
ACYP2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699425 | ABM | 1.0 ug DNA | EUR 616.8 |
ACYP2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699426 | ABM | 1.0 ug DNA | EUR 616.8 |
NFASC Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699427 | ABM | 1.0 ug DNA | EUR 1626 |
NFASC Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699431 | ABM | 1.0 ug DNA | EUR 1626 |
NFASC Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699432 | ABM | 1.0 ug DNA | EUR 1626 |
ADRB1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699433 | ABM | 1.0 ug DNA | EUR 818.4 |
ADRB1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699437 | ABM | 1.0 ug DNA | EUR 818.4 |
ADRB1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699438 | ABM | 1.0 ug DNA | EUR 818.4 |
RB1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699439 | ABM | 1.0 ug DNA | EUR 1626 |
RB1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699443 | ABM | 1.0 ug DNA | EUR 1626 |
RB1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699444 | ABM | 1.0 ug DNA | EUR 1626 |
PLEC Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699445 | ABM | 1.0 ug DNA | EUR 7941.6 |
PLEC Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699449 | ABM | 1.0 ug DNA | EUR 7941.6 |
PLEC Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699450 | ABM | 1.0 ug DNA | EUR 7941.6 |
TGFB3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699451 | ABM | 1.0 ug DNA | EUR 818.4 |
TGFB3 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699455 | ABM | 1.0 ug DNA | EUR 818.4 |
TGFB3 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699456 | ABM | 1.0 ug DNA | EUR 818.4 |
PTGER3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699457 | ABM | 1.0 ug DNA | EUR 818.4 |
PTGER3 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699461 | ABM | 1.0 ug DNA | EUR 818.4 |
PTGER3 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699462 | ABM | 1.0 ug DNA | EUR 818.4 |
PLEC Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699463 | ABM | 1.0 ug DNA | EUR 7929.6 |
PLEC Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699467 | ABM | 1.0 ug DNA | EUR 7929.6 |
PLEC Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699468 | ABM | 1.0 ug DNA | EUR 7929.6 |
BCL2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699469 | ABM | 1.0 ug DNA | EUR 616.8 |
BCL2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699473 | ABM | 1.0 ug DNA | EUR 616.8 |
BCL2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699474 | ABM | 1.0 ug DNA | EUR 616.8 |
Siah1a Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699475 | ABM | 1.0 ug DNA | EUR 616.8 |
Siah1a Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699479 | ABM | 1.0 ug DNA | EUR 616.8 |
Siah1a Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699480 | ABM | 1.0 ug DNA | EUR 616.8 |
CDC42SE2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699481 | ABM | 1.0 ug DNA | EUR 616.8 |
CDC42SE2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699485 | ABM | 1.0 ug DNA | EUR 616.8 |
CDC42SE2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699486 | ABM | 1.0 ug DNA | EUR 616.8 |
RYR2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699487 | ABM | 1.0 ug DNA | EUR 8602.8 |
RYR2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699491 | ABM | 1.0 ug DNA | EUR 8602.8 |
RYR2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699492 | ABM | 1.0 ug DNA | EUR 8602.8 |
PRKG1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699493 | ABM | 1.0 ug DNA | EUR 1626 |
PRKG1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699497 | ABM | 1.0 ug DNA | EUR 1626 |
PRKG1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699498 | ABM | 1.0 ug DNA | EUR 1626 |
Tas2r113 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699499 | ABM | 1.0 ug DNA | EUR 616.8 |
Tas2r113 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699503 | ABM | 1.0 ug DNA | EUR 616.8 |
Tas2r113 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699504 | ABM | 1.0 ug DNA | EUR 616.8 |
PTPN11 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699505 | ABM | 1.0 ug DNA | EUR 818.4 |
PTPN11 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699509 | ABM | 1.0 ug DNA | EUR 818.4 |
PTPN11 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699510 | ABM | 1.0 ug DNA | EUR 818.4 |
CASR Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699511 | ABM | 1.0 ug DNA | EUR 1626 |
CASR Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699515 | ABM | 1.0 ug DNA | EUR 1626 |
CASR Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699516 | ABM | 1.0 ug DNA | EUR 1626 |
PTPN11 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699517 | ABM | 1.0 ug DNA | EUR 818.4 |
PTPN11 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699521 | ABM | 1.0 ug DNA | EUR 818.4 |
PTPN11 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699522 | ABM | 1.0 ug DNA | EUR 818.4 |
RHEB Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699523 | ABM | 1.0 ug DNA | EUR 616.8 |
RHEB Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699527 | ABM | 1.0 ug DNA | EUR 616.8 |
RHEB Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699528 | ABM | 1.0 ug DNA | EUR 616.8 |
TGFB1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699529 | ABM | 1.0 ug DNA | EUR 818.4 |
TGFB1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699533 | ABM | 1.0 ug DNA | EUR 818.4 |
TGFB1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699534 | ABM | 1.0 ug DNA | EUR 818.4 |
HTR2A Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699535 | ABM | 1.0 ug DNA | EUR 818.4 |
HTR2A Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699539 | ABM | 1.0 ug DNA | EUR 818.4 |
HTR2A Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699540 | ABM | 1.0 ug DNA | EUR 818.4 |
PLA2G2A Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699541 | ABM | 1.0 ug DNA | EUR 616.8 |
PLA2G2A Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699545 | ABM | 1.0 ug DNA | EUR 616.8 |
PLA2G2A Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699546 | ABM | 1.0 ug DNA | EUR 616.8 |
HIF1A Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699547 | ABM | 1.0 ug DNA | EUR 1626 |
HIF1A Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699551 | ABM | 1.0 ug DNA | EUR 1626 |
HIF1A Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699552 | ABM | 1.0 ug DNA | EUR 1626 |
PTGER2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699553 | ABM | 1.0 ug DNA | EUR 818.4 |
PTGER2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699557 | ABM | 1.0 ug DNA | EUR 818.4 |
PTGER2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699558 | ABM | 1.0 ug DNA | EUR 818.4 |
CELF2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699559 | ABM | 1.0 ug DNA | EUR 818.4 |
CELF2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699563 | ABM | 1.0 ug DNA | EUR 818.4 |
CELF2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699564 | ABM | 1.0 ug DNA | EUR 818.4 |
Ins2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699565 | ABM | 1.0 ug DNA | EUR 616.8 |
Ins2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699569 | ABM | 1.0 ug DNA | EUR 616.8 |
Ins2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699570 | ABM | 1.0 ug DNA | EUR 616.8 |
GNAS Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699571 | ABM | 1.0 ug DNA | EUR 616.8 |
GNAS Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699575 | ABM | 1.0 ug DNA | EUR 616.8 |
GNAS Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699576 | ABM | 1.0 ug DNA | EUR 616.8 |
Ins1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699577 | ABM | 1.0 ug DNA | EUR 616.8 |
Ins1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699581 | ABM | 1.0 ug DNA | EUR 616.8 |
Ins1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV699582 | ABM | 1.0 ug DNA | EUR 616.8 |
SLC12A1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699583 | ABM | 1.0 ug DNA | EUR 1626 |
These research recommend that cell-surface attachment stabilizes particles and alters neutralization kinetics. Our experiments present novel perception into the underexplored cell-cell transmission of pseudotyped particles.
